Annual CFF
$870.52 M
+$617.47 M+244.01%
30 September 2024
Summary:
Arrowhead Pharmaceuticals annual cash flow from financing activities is currently $870.52 million, with the most recent change of +$617.47 million (+244.01%) on 30 September 2024. During the last 3 years, it has risen by +$859.22 million (+7600.31%). ARWR annual CFF is now at all-time high.ARWR Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$389.09 M
+$338.70 M+672.20%
30 September 2024
Summary:
Arrowhead Pharmaceuticals quarterly cash flow from financing activities is currently $389.09 million, with the most recent change of +$338.70 million (+672.20%) on 30 September 2024. Over the past year, it has increased by +$388.82 million (+145626.22%). ARWR quarterly CFF is now -9.68% below its all-time high of $430.78 million, reached on 31 March 2024.ARWR Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$870.52 M
+$388.27 M+80.51%
30 September 2024
Summary:
Arrowhead Pharmaceuticals TTM cash flow from financing activities is currently $870.52 million, with the most recent change of +$388.27 million (+80.51%) on 30 September 2024. Over the past year, it has increased by +$867.78 million (+31624.49%). ARWR TTM CFF is now at all-time high.ARWR TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ARWR Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +244.0% | +10000.0% | +10000.0% |
| 3 y3 years | +7600.3% | +10000.0% | +10000.0% |
| 5 y5 years | +1211.4% | +53.5% | +233.8% |
ARWR Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +7600.3% | -9.7% | >+9999.0% | at high | >+9999.0% |
| 5 y | 5 years | at high | +7600.3% | -9.7% | >+9999.0% | at high | >+9999.0% |
| alltime | all time | at high | >+9999.0% | -9.7% | >+9999.0% | at high | >+9999.0% |
Arrowhead Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | $870.52 M(+244.0%) | $389.09 M(+672.2%) | $870.52 M(+80.5%) |
| June 2024 | - | $50.39 M(-88.3%) | $482.25 M(+11.4%) |
| Mar 2024 | - | $430.78 M(>+9900.0%) | $433.00 M(>+9900.0%) |
| Dec 2023 | - | $267.00 K(-67.5%) | $2.74 M(-98.9%) |
| Sept 2023 | $253.05 M(+288.2%) | $821.00 K(-27.7%) | $253.05 M(-0.0%) |
| June 2023 | - | $1.14 M(+118.5%) | $253.09 M(-19.0%) |
| Mar 2023 | - | $520.00 K(-99.8%) | $312.55 M(-0.4%) |
| Dec 2022 | - | $250.58 M(>+9900.0%) | $313.88 M(+381.5%) |
| Sept 2022 | $65.19 M(+476.6%) | $855.00 K(-98.6%) | $65.19 M(+0.1%) |
| June 2022 | - | $60.60 M(+3182.8%) | $65.15 M(+792.3%) |
| Mar 2022 | - | $1.85 M(-2.1%) | $7.30 M(-9.7%) |
| Dec 2021 | - | $1.89 M(+131.3%) | $8.09 M(-28.5%) |
| Sept 2021 | $11.30 M(-95.6%) | $815.00 K(-70.4%) | $11.30 M(-1.7%) |
| June 2021 | - | $2.75 M(+4.6%) | $11.49 M(+5.7%) |
| Mar 2021 | - | $2.63 M(-48.4%) | $10.87 M(+13.6%) |
| Dec 2020 | - | $5.10 M(+407.7%) | $9.57 M(-96.3%) |
| Sept 2020 | $257.95 M(+288.6%) | $1.00 M(-52.9%) | $257.95 M(-0.3%) |
| June 2020 | - | $2.13 M(+59.9%) | $258.78 M(-0.2%) |
| Mar 2020 | - | $1.33 M(-99.5%) | $259.41 M(-0.5%) |
| Dec 2019 | - | $253.48 M(>+9900.0%) | $260.75 M(+292.8%) |
| Sept 2019 | $66.38 M(+10.7%) | $1.83 M(-33.7%) | $66.38 M(+0.4%) |
| June 2019 | - | $2.77 M(+3.6%) | $66.12 M(+2.0%) |
| Mar 2019 | - | $2.67 M(-95.5%) | $64.81 M(-45.6%) |
| Dec 2018 | - | $59.11 M(+3662.4%) | $119.04 M(+98.6%) |
| Sept 2018 | $59.95 M(+397.3%) | $1.57 M(+8.0%) | $59.95 M(+2.9%) |
| June 2018 | - | $1.45 M(-97.4%) | $58.26 M(+2.6%) |
| Mar 2018 | - | $56.90 M(>+9900.0%) | $56.81 M(>+9900.0%) |
| Dec 2017 | - | $26.30 K(-121.5%) | $46.10 K(-99.6%) |
| Sept 2017 | $12.06 M(-78.1%) | -$122.30 K(<-9900.0%) | $12.06 M(-81.7%) |
| June 2017 | - | $0.00(-100.0%) | $65.82 M(-3.2%) |
| Mar 2017 | - | $142.10 K(-98.8%) | $68.03 M(+0.5%) |
| Dec 2016 | - | $12.04 M(-77.6%) | $67.66 M(+22.7%) |
| Sept 2016 | $55.13 M(>+9900.0%) | $53.64 M(+2332.8%) | $55.13 M(+3292.9%) |
| June 2016 | - | $2.21 M(-1091.5%) | $1.62 M(-356.5%) |
| Mar 2016 | - | -$222.40 K(-55.0%) | -$633.60 K(+64.8%) |
| Dec 2015 | - | -$494.60 K(-461.3%) | -$384.40 K(-232.3%) |
| Sept 2015 | $290.50 K(-99.8%) | $136.90 K(-355.9%) | $290.50 K(-57.9%) |
| June 2015 | - | -$53.50 K(-299.6%) | $689.40 K(-86.4%) |
| Mar 2015 | - | $26.80 K(-85.1%) | $5.08 M(-95.9%) |
| Dec 2014 | - | $180.30 K(-66.3%) | $122.71 M(-33.8%) |
| Sept 2014 | $185.29 M(+318.4%) | $535.80 K(-87.7%) | $185.29 M(-0.8%) |
| June 2014 | - | $4.34 M(-96.3%) | $186.76 M(-14.2%) |
| Mar 2014 | - | $117.65 M(+87.4%) | $217.73 M(+109.8%) |
| Dec 2013 | - | $62.77 M(+3033.8%) | $103.78 M(+134.3%) |
| Sept 2013 | $44.29 M(+311.3%) | $2.00 M(-94.3%) | $44.29 M(-7.3%) |
| June 2013 | - | $35.31 M(+853.3%) | $47.79 M(+215.7%) |
| Mar 2013 | - | $3.70 M(+12.9%) | $15.14 M(+20.0%) |
| Dec 2012 | - | $3.28 M(-40.4%) | $12.62 M(+17.2%) |
| Sept 2012 | $10.77 M | $5.50 M(+107.5%) | $10.77 M(+10.8%) |
| June 2012 | - | $2.65 M(+124.7%) | $9.72 M(+37.3%) |
| Mar 2012 | - | $1.18 M(-17.5%) | $7.08 M(-7.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2011 | - | $1.43 M(-67.8%) | $7.62 M(+22.3%) |
| Sept 2011 | $6.23 M(-48.3%) | $4.45 M(>+9900.0%) | $6.23 M(+197.1%) |
| June 2011 | - | $13.90 K(-99.2%) | $2.10 M(-79.6%) |
| Mar 2011 | - | $1.72 M(+3870.4%) | $10.25 M(+12.8%) |
| Dec 2010 | - | $43.30 K(-86.4%) | $9.09 M(-24.5%) |
| Sept 2010 | $12.04 M(+86.2%) | $319.10 K(-96.1%) | $12.04 M(-15.6%) |
| June 2010 | - | $8.17 M(+1363.6%) | $14.27 M(+142.0%) |
| Mar 2010 | - | $558.10 K(-81.4%) | $5.90 M(+0.1%) |
| Dec 2009 | - | $2.99 M(+17.4%) | $5.89 M(-8.9%) |
| Sept 2009 | $6.46 M(-59.9%) | $2.55 M(-1346.5%) | $6.46 M(-67.3%) |
| June 2009 | - | -$204.60 K(-137.2%) | $19.76 M(-1.0%) |
| Mar 2009 | - | $549.40 K(-84.6%) | $19.96 M(+2.8%) |
| Dec 2008 | - | $3.57 M(-77.5%) | $19.41 M(+20.3%) |
| Sept 2008 | $16.13 M(+3.5%) | $15.84 M(>+9900.0%) | $16.13 M(+5161.9%) |
| June 2008 | - | $0.00(0.0%) | $306.60 K(-98.0%) |
| Mar 2008 | - | $0.00(-100.0%) | $15.56 M(-0.0%) |
| Dec 2007 | - | $290.00 K(+1647.0%) | $15.56 M(-0.2%) |
| Sept 2007 | $15.59 M(-25.4%) | $16.60 K(-99.9%) | $15.59 M(-7.6%) |
| June 2007 | - | $15.25 M(>+9900.0%) | $16.87 M(+917.9%) |
| Mar 2007 | - | $4000.00(-98.7%) | $1.66 M(-92.2%) |
| Dec 2006 | - | $316.20 K(-75.8%) | $21.20 M(+1.5%) |
| Sept 2006 | $20.89 M(+0.7%) | $1.30 M(+3792.8%) | $20.89 M(+6.5%) |
| June 2006 | - | $33.50 K(-99.8%) | $19.62 M(-49.1%) |
| Mar 2006 | - | $19.55 M(>+9900.0%) | $38.54 M(+88.1%) |
| Dec 2005 | - | $4000.00(-89.4%) | $20.48 M(-1.3%) |
| Sept 2005 | $20.74 M(+110.1%) | $37.60 K(-99.8%) | $20.74 M(+0.9%) |
| June 2005 | - | $18.95 M(+1169.4%) | $20.56 M(+1014.1%) |
| Mar 2005 | - | $1.49 M(+465.2%) | $1.85 M(-81.1%) |
| Dec 2004 | - | $264.10 K(-284.3%) | $9.74 M(-1.3%) |
| Sept 2004 | $9.87 M(+551.6%) | -$143.30 K(-161.7%) | $9.87 M(-14.0%) |
| June 2004 | - | $232.10 K(-97.5%) | $11.48 M(+2.0%) |
| Mar 2004 | - | $9.39 M(+2286.0%) | $11.26 M(+490.5%) |
| Dec 2003 | - | $393.50 K(-73.2%) | $1.91 M(+25.9%) |
| Sept 2003 | $1.51 M(+1105.3%) | $1.47 M(>+9900.0%) | $1.51 M(+6346.4%) |
| June 2003 | - | $12.10 K(-64.7%) | $23.50 K(-79.4%) |
| Mar 2003 | - | $34.30 K(+2538.5%) | $114.30 K(+16.2%) |
| Dec 2002 | - | $1300.00(-105.4%) | $98.40 K(-21.7%) |
| Sept 2002 | $125.70 K(+56.9%) | -$24.20 K(-123.5%) | $125.70 K(-23.3%) |
| June 2002 | - | $102.90 K(+459.2%) | $163.90 K(+112.6%) |
| Mar 2002 | - | $18.40 K(-35.7%) | $77.10 K(-15.8%) |
| Dec 2001 | - | $28.60 K(+104.3%) | $91.60 K(+14.2%) |
| Sept 2001 | $80.10 K(-3.1%) | $14.00 K(-13.0%) | $80.20 K(-9.6%) |
| June 2001 | - | $16.10 K(-51.1%) | $88.70 K(-33.7%) |
| Mar 2001 | - | $32.90 K(+91.3%) | $133.80 K(+33.3%) |
| Dec 2000 | - | $17.20 K(-23.6%) | $100.40 K(+21.4%) |
| Sept 2000 | $82.70 K(+141.1%) | $22.50 K(-63.2%) | $82.70 K(+37.4%) |
| June 2000 | - | $61.20 K(<-9900.0%) | $60.20 K(-6120.0%) |
| Mar 2000 | - | -$500.00(0.0%) | -$1000.00(+100.0%) |
| Dec 1999 | - | -$500.00 | -$500.00 |
| Sept 1999 | $34.30 K(<-9900.0%) | - | - |
| Sept 1998 | -$200.00(-95.5%) | - | - |
| Sept 1997 | -$4400.00 | - | - |
FAQ
- What is Arrowhead Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals annual CFF year-on-year change?
- What is Arrowhead Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals quarterly CFF year-on-year change?
- What is Arrowhead Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals TTM CFF year-on-year change?
What is Arrowhead Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of ARWR is $870.52 M
What is the all time high annual CFF for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high annual cash flow from financing activities is $870.52 M
What is Arrowhead Pharmaceuticals annual CFF year-on-year change?
Over the past year, ARWR annual cash flow from financing activities has changed by +$617.47 M (+244.01%)
What is Arrowhead Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of ARWR is $389.09 M
What is the all time high quarterly CFF for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high quarterly cash flow from financing activities is $430.78 M
What is Arrowhead Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, ARWR quarterly cash flow from financing activities has changed by +$388.82 M (+145626.22%)
What is Arrowhead Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of ARWR is $870.52 M
What is the all time high TTM CFF for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high TTM cash flow from financing activities is $870.52 M
What is Arrowhead Pharmaceuticals TTM CFF year-on-year change?
Over the past year, ARWR TTM cash flow from financing activities has changed by +$867.78 M (+31624.49%)